Personalized MedicineThe technologies are here

 Are you ready to invest and help

patients?

Opportunity Analysis Project for the Stanford Technology Ventures Course 2012

Submitted by Team Neuropeptide

What is personalized medicine?

Personalized medicine is generally understood as the use of molecular analysis to achieve optimal medical outcomes in the management of patient’s disease or disease predisposition(Based on the definition from the Personalized Medicine Coalition) Our primary business objectives:

i) Development of a comprehensive machine learning framework to identify molecular signatures in patients with the highest unmet medical needs i.e. oncology/cancer

ii) Development of personalized medical treatments that might include targeted personalized drugs tailored to individual genetics

Patients with unmet medical needs want more effective treatments with fewer side effects

● Over 50% of prescribed drugs are not efficacious. The option for healthcare providers and patients was an expensive and inefficient trial and error approach based on arcane technologies. Our society can not afford the status quo anymore

● Patients as well as healthy

people desire personalized medical care

Personalized Medicine Attitude Survey Results, VL Neuropeptide Team, 2012

Changes are coming...

• The paradigm shift in health care is here to stay and visionary informatics and biotech entrepreneurs have been positioning themselves to gain early entry advantage in this new era • FDA getting proactive to prevent adverse drug effects • FDA getting proactive at supporting personalized medicine technologies and research initiativesBiomarkers, SNPs, NGS, Microarrays, Genomics, Proteomics, Imaging, Diagnostics and Targeted Personalized Therapeutics

A Mandate: The right drug to the right patient at the right time (Leroy Hood)

• Multiple approaches to develop the best treatment for the individual patient • Capitalize on current advances in computational biology to speed up the discovery of personalized biologics • Started with diagnostics moving fast into personalized therapeutics Some Venture Capital firms shifted their investments overseas where regulatory approvals come quicker;The U.S. Food and Drug Administration is taking steps to address some of the industry's concerns; the agency plans to streamline regulations and speed up the approval process for some drugsBloomberg.com, Oct 6, 2011

How should medicine be reformed?

● The progress of clinical trials should be made readily available ● Patient privacy should be observed if requested by the patient, but

depersonalized genomic and clinical data should be freely shared and exchanged

● The power of outside interests (big pharma, insurance, etc.) should be explicitly curtailed. An industry-wide black list for cases of collusion, probable bias, and misleading results should be kept with free access

● The field should embrace computation and big data to accelerate research and create a framework for personalized medicine

● Better integration of computers in clinical practice and better utilization of data produced

● Better MR scanners and better BCIs

What are the biggest roadblocks in medicine today?

● Perceived unbalanced use of personal information by healthcare and insurance entities may be generating mistrust and a feeling of helplessness in people

● Low quality of body of research caused by an enormous amount of biased and unverified experimental findings usually due to outside interests or ulterior motives

● Slow introduction of computational power into the medical field in general

● The idea that complex psychological phenomena can be explained by quite simple biological factors (alone)

● Hierarchical and traditional structure ● Lack of emancipated patient participation

What are the advantages of personalization?

Efficient Medical CareArcane Reactive Medical Care

Costly and inefficient trial and error approach

Improved Quality Care

Adapted from public Personalized Medicine Coalition report

Not just personalized drug selection but personalized drug development!

Arcane Reactive Medical Care Efficient Medical Care

Not just personalized drug selection but personalized drug development!

Costly and inefficient trial and error approach

Improved Quality Care

Adapted from public Personalized Medicine Coalition report, www.PersonalizedMedicineCoalition.org

What are the advantages of personalization?

The goal of the Personalized Medicine Coalition

Figure taken from the PMC website www.PersonalizedMedicineCoalition.org

Genotype Analysis AttitudeData from our survey

How likely are you to get your genotype confidentially analyzed for you (possible for $300)?

Personalized Medicine Attitude Survey Results, VL Neuropeptide Team, 2012

Personalized drug consumer attitude data from our survey

How likely are you to get your whole genome sequenced and analyzed for the development of your own personalized experimental drug(s)?

Conclusion:Our sample size is not large enough (n=55) to draw a statistically relevant conclusion with respect to the degree of willingness to have own genome sequenced and analyzed for development of own drugs.However, it is apparent from the responses that people that are not likely to do it are a minority with respect to those that could eventually do it. We predict that with proper education on the subject, ~75% of the people will be very likely to do it.

n=55

Personalized Medicine Attitude Survey Results, VL Neuropeptide Team, 2012

Personalized health care consumer attitude data from our survey

When do you think it will be possible to provide personalized health care? n=55

Conclusion:From a sample size n=55, we observe an overall optimistic public attitude toward the ability to realize and implement full personalized health care in the coming years.We hypothesize that with better education about the subject, the general perception of the public will tend to be skewed toward shorter development and implementation times

Personalized Medicine Attitude Survey Results, VL Neuropeptide Team, 2012

Market Projections in Personalized Medicine

● Projected to grow 11.56% annually

● Estimated

U$ 232MM

● Expected to double by 2015 to over 450MM

● Mostly from

Genomics and Proteomics

Bay area proactive http://2013sv.pmwcintl.com/